GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections
February 27 2023 - 9:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced the
presentation of results from a clinical study of a combinational
HIV therapy that included GeoVax’s HIV vaccine candidate, MVA62B.
The data were presented at the Conference on Retroviruses and
Opportunistic Infections (CROI) held February 19-22, 2023, in
Seattle, Washington.
The data were generated, in a clinical trial led by researchers
at the University of California, San Francisco (UCSF), to develop a
combinational therapy aimed at reducing or eliminating viral
replication in the absence of antiviral medications in HIV-positive
individuals (a “functional cure”). The primary objectives of the
proof-of-concept trial were to assess the safety and tolerability
of the combinational therapy and to determine the viral load
“set-point” during antiviral treatment interruption. Secondary
objectives were to assess immune responses and changes in viral
reservoir status.
The clinical trial was led by Steven Deeks, M.D. of UCSF, a
world leader in therapeutic approaches to HIV infections, and was
one of the most comprehensive tests to date for the ability of
synergistic approaches to control HIV infection. The studies were
conducted with funding from amfAR, The Foundation for AIDS
Research.
Mark Newman, Ph.D., GeoVax’s Chief Scientific Officer,
commented, “The goal of this trial was to induce immune responses
that could significantly limit HIV replication in patients in the
absence of antiviral drugs. This would represent a highly
significant therapeutic benefit for HIV infected patients. The data
indicated very high levels of immunogenicity of the treatment,
particularly the induction of T cell immunity, even though HIV
infection compromises the immune system. Viral rebound kinetics
also appeared to be impacted positively, measured as reduced viral
load and delayed return of peak levels.”
“We are pleased that GeoVax’s MVA-vectored HIV vaccine was
selected to be a part of the experimental combination therapy and
contributed to the positive findings,” Dr. Newman continued. “The
GeoVax MVA62B was previously tested in multiple clinical trials as
a component of vaccine regimens designed to induce immune responses
that prevent HIV infection. We are continuing development of the
GeoVax MVA-VLP vaccine platform targeting multiple viral diseases,
including COVID-19, MPOX, Smallpox and hemorrhagic fever viruses,
such as Lassa Fever and Ebola.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for cancers and many of the
world’s most threatening infectious diseases. The company’s lead
program in oncology is a novel oncolytic solid tumor gene-directed
therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical
trial for advanced head and neck cancers. GeoVax’s lead infectious
disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in two Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a COVID-19 vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical
trial evaluating the vaccine as a more robust, durable COVID-19
booster among healthy patients who previously received the mRNA
vaccines. GeoVax has a leadership team who have driven significant
value creation across multiple life science companies over the past
several decades. For more information, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
GeoVax Media Relations
Contact:
Nancy Turett914-434-0311nmturett@geovax.com
GeoVax Investor Relations
Contact:
Rich CockrellCG Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2024 to Jul 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2023 to Jul 2024